Research

Novel small-molecule antiviral compound protects monkeys from deadly Ebola virus

Rhesus monkeys were completely protected from Ebola virus when treated three days after infection with a compound that blocks the virus's ability to replicate. These encouraging preclinical results suggest the compound, known as GS-5734, should be further developed as a potential treatment, according to research findings published online this week in the journal Nature.

Ebola virus causes severe hemorrhagic fever in humans and nonhuman primates with high mortality rates and continues to emerge in new geographic locations, including Western Africa, the site of the largest outbreak to date. Since December 2013, over 28,600 cases have been reported in Guinea, Liberia and Sierra Leone, with over 11,300 deaths, according to the World Health Organization. Although several clinical trials have been conducted or are currently underway, there are no licensed vaccines or therapies against Ebola virus.

Travis Warren, Ph.D., a principal investigator at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and first author of the paper, said the work published today is the result of continuing collaborations between USAMRIID and Gilead Sciences of Foster City, Calif. Scientists at the Centers for Disease Control and Prevention (CDC) also contributed by performing initial screening of the Gilead Sciences compound library to find molecules with promising antiviral activity.

That initial work identified the precursor to GS-5734, a small-molecule antiviral agent, which led to the effort by Gilead and USAMRIID to further refine, develop and profile the compound. Led by USAMRIID Science Director Sina Bavari, Ph.D., the paper's senior author, the research team used cell culture and animal models to demonstrate the compound's antiviral activity against several pathogens, including Ebola virus.

In animal studies, treatment initiated on day 3 post-infection with Ebola virus resulted in 100 percent survival of the monkeys. The animals also exhibited a substantial reduction in viral load and a marked decrease in the physical signs of disease.

"GS-5734 is a novel nucleotide analog prodrug. It inhibits Ebola virus by blocking the virus's ability to replicate its own genetic material," said Warren. "With this process inhibited, the virus can't make copies of itself. Additionally, we saw no evidence from genetic sequence analyses that the virus was able to generate resistance to GS-5734."

In cell culture studies, led at USAMRIID by Veronica Soloveva, Ph.D., GS-5734 was active against a broad spectrum of viral pathogens. These included Middle East Respiratory Syndrome (MERS) virus, Marburg virus, and multiple variants of Ebola virus, including the Makona strain causing the most recent outbreak in Western Africa.

"GS-5734 has several favorable characteristics for potential treatment of Ebola virus disease in humans. It is made using well-controlled chemical synthesis procedures, is stable, and can be made on a large scale," Bavari commented. "It shows substantive post-exposure protection against Ebola virus in nonhuman primates, even when treatments were started after virus had spread to the blood in some animals."

Taken together, the robust therapeutic efficacy observed in primates, the favorable drug-like properties, and the potential for broad-spectrum antiviral activity suggest that further development of GS-5734 for the treatment of Ebola virus and other viral infections is warranted, Bavari said.

According to Tomas Cihlar, Ph.D., of Gilead Sciences, the company is currently conducting a series of phase I clinical studies in healthy human volunteers to establish the safety and pharmacokinetic profile of GS-5734. The compound also has been provided for compassionate use to treat two patients with Ebola virus infection, both of whom were discharged from the hospital. One of them was the Scottish nurse with recrudescent disease and the other was an acutely infected newborn, thus far the last identified case of Ebola virus infection in Guinea.

"With the hope that the West African outbreak will remain under control, we are exploring alternative options for the development path of GS-5734, including potential use of the animal efficacy rule," Cihlar said. The animal rule is a regulatory mechanism under which the U.S. Food and Drug Administration may consider efficacy findings from adequate and well-controlled animal studies of a drug in cases where it is not feasible or ethical to conduct human trials.

Research on Ebola virus is conducted in Biosafety Level 4 (maximum containment) laboratories, where investigators wear positive-pressure "space suits" and breathe filtered air as they work. USAMRIID is the only organization in the Department of Defense with Biosafety Level 4 capabilities, and its research benefits both military personnel and civilians.

USAMRIID's mission is to provide leading-edge medical capabilities to deter and defend against current and emerging biological threat agents. The Institute plays a key role as the lead military medical research laboratory for the Defense Threat Reduction Agency's Joint Science and Technology Office for Chemical and Biological Defense. USAMRIID is a subordinate element of the U.S. Army Medical Research and Materiel Command. For more information, visit http://www.usamriid.army.mil.

T Warren et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature DOI: 10.1038/nature17180 (2016)

Funding: Studies at USAMRIID were in part supported by The Joint Science and Technology Office for Chemical and Biological Defense (JSTO-CBD) of the Defense Threat Reduction Agency (DTRA) under plan #CB10218.

Work in the Fearns laboratory was supported by the National Institutes of Health, NIH R01AI113321.

Contributors: Travis K. Warren, Robert Jordan, Michael K. Lo, Adrian S. Ray, Richard L. Mackman, Veronica Soloveva, Dustin Siegel, Michel Perron, Roy Bannister, Hon C. Hui, Nate Larson, Robert Strickley, Jay Wells, Kelly S. Stuthman, Sean A. Van Tongeren, Nicole L. Garza, Ginger Donnelly, Amy C. Shurtleff, Cary J. Retterer, Dima Gharaibeh, Rouzbeh Zamani, Tara Kenny, Brett P. Eaton, Elizabeth Grimes, Lisa S. Welch, Laura Gomba, Catherine L. Wilhelmsen, Donald K. Nichols, Jonathan E. Nuss, Elyse R. Nagle, Jeffrey R. Kugelman, Gustavo Palacios, Edward Doerffler, Sean Neville, Ernest Carra, Michael O. Clarke, Lijun Zhang, Willard Lew, Bruce Ross, Queenie Wang, Kwon Chun, Lydia Wolfe, Darius Babusis, Yeojin Park, Kirsten M. Stray, Iva Trancheva, Joy Y. Feng, Ona Barauskas, Yili Xu, Pamela Wong, Molly R. Braun, Mike Flint, Laura K. McMullan, Shan-Shan Chen, Rachel Fearns, Swami Swaminathan, Douglas L. Mayers, Christina F. Spiropoulou, William A. Lee, Stuart T. Nichol, Tomas Cihlar and Sina Bavari.

Most Popular Now

A new method cuts the cost of drug-…

EPFL (École polytechnique fédérale de Lausanne) scientists design a new method to cheaply produce some of the most important chemical compounds in the pharmaceutical indu...

Read more

Six leading scientists to receive p…

Today Novartis announced that six scientists will receive the 2016 Novartis Prizes for Immunology at the upcoming 16th International Congress of Immunology (ICI) in Melbo...

Read more

Pfizer announces publication of new…

Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid po...

Read more

Bayer and CRISPR Therapeutics joint…

Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, started its operations in Cambridge, MA, U.S. In December, 2015 Bayer and CRISPR Therape...

Read more

Natural compound from a deep-water …

Scientists at Florida Atlantic University's Harbor Branch Oceanographic Institute found that a deep-water marine sponge collected off of Fort Lauderdale's coast contains ...

Read more

AstraZeneca and Lilly receive FDA F…

AstraZeneca and Eli Lilly and Company (Lilly) today announced they have received US Food and Drug Administration (FDA) Fast Track designation for the development programm...

Read more

Researchers develop safer opioid pa…

An international team of researchers - led by scientists at UC San Francisco, Stanford University, the University of North Carolina (UNC), and the Friedrich-Alexander Uni...

Read more

Amgen and Advaxis enter global canc…

Amgen (NASDAQ:AMGN) and Advaxis, Inc. (NASDAQ:ADXS) announced a global agreement for the development and commercialization of Advaxis' ADXS-NEO, a novel, preclinical inve...

Read more

Legions of nanorobots target cancer…

Researchers from Polytechnique Montréal, Université de Montréal and McGill University have just achieved a spectacular breakthrough in cancer research. They have develope...

Read more

Why is breast cancer common but hea…

Malignant cancers strike certain organs, such as the colon or breast, more often than others. In an Opinion publishing August 9 in Trends in Cancer, researchers propose t...

Read more

Esketamine receives Breakthrough Th…

Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that the U.S. Food and Drug Administration (FDA) has gran...

Read more

Diabetes drug may also offer vascul…

Obesity and Type 2 diabetes are associated with vascular stiffening and the development of cardiovascular disease. Obese and diabetic premenopausal women are most at risk...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

© World Pharma News 2006 - 2016